SUNNYVALE, CA. — Parkinson’s Institute and Clinical Center announced today that it is collaborating with Kainos Medicine, Korea on a new drug therapy.

Kainos Medicine recently developed KM-819, which is an innovative new investigational drug based on a novel mode of action that protects dopaminergic neurons from death by inhibiting the function of FAF1 which is known to induce cell death. KM-819 showed efficacy in neuroprotection and inhibiting behavioral impairment induced by MPTP treatment in animals.

Parkinson’s Institute and Clinical Center, who focus on the early detection and complete cure of Parkinson’s are trying to find innovative ways to conquer the disease. “One way to do this is to test novel approaches by analyzing stem cells with unique mutations that may cause Parkinson’s,” says Dr. Carrolee Barlow, CEO, Parkinson’s Institute and Clinical Center.

The Parkinson’s Institute and Clinical Center and Kainos will conduct preclinical studies to analyze KM-819 in our patient’s stem cells which have various disease causing genetic mutations. “Hopefully, this study will give clues for new drug discovery and development to help us achieve our goal of stopping Parkinson’s in its tracks,” says Dr. Barlow.

“We are very excited to partner with Kainos,” says Dr. Barlow. “They are a critical resource for our patients and are helping us find a cure.”

About the Parkinson’s Institute and Clinical Center:

The Parkinson’s Institute and Clinical Center is at the forefront of patient care and therapy development. We are the nation’s only Institute that provides patient care, basic science research, and clinical research in one integrated model. Our unique freestanding organization directly connects research to patient care – from the “lab bench to bedside.” For 30 years, our team of epidemiologists, physicians, scientists, and therapists, have been at the forefront of every clinical and scientific discovery in the field of Parkinson’s research.

Since our inception, patients have come from 38 states and many foreign countries for their care. We have managed more than 135 clinical research trials, medically evaluating more than 95 different drugs and therapies for Parkinson’s. The result: our Institute has been directly involved in bringing every Parkinson’s drug currently available to the market. The Institute is at the forefront of discovering and developing the latest, most innovative treatments and therapies for people living with Parkinson’s.

For more information visit or call (408) 734-2800.

Download this press release.